Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program

被引:9
|
作者
Benito, Llucia [1 ,2 ]
Travier, Noemie [2 ,3 ]
Binefa, Gemma [2 ,3 ,4 ]
Vidal, Carmen [2 ,3 ]
Espinosa, Jose [2 ,3 ]
Mila, Nuria [2 ,3 ,4 ]
Garcia, Montse [2 ,3 ,4 ]
机构
[1] Univ Barcelona, Sch Nursing, Fundamental Care & Med Surg Nursing Dept, Hosp Llobregat, Barcelona, Spain
[2] Hosp Llobregat, Inst Biomed Res, IDI BELL, Barcelona, Spain
[3] Hosp Llobregat, Canc Prevent & Control Program, Catalan Inst Oncol, Barcelona, Spain
[4] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain
关键词
RANDOMIZED CONTROLLED-TRIAL; 4; ROUNDS; CATALONIA; PARTICIPATION; PERFORMANCE; PILOT; SPAIN;
D O I
10.1158/1940-6207.CAPR-18-0091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Longitudinal adherence is a critical component of the efficacy of stool-based screening programs because they should be repeated every 1-2 years. Few data have been published on the uptake in multiple rounds of fecal occult blood test-based (FOBT) colorectal cancer (CRC) screening. We calculated two measures of longitudinal adherence to biennial FOBT (guaiac fecal occult blood test:gFOBT or fecal immunochemical test: FIT) to better understand its impact on the programmatic effectiveness of a population-based CRC screening program (2000-2017). Ongoing population-based CRC program of men and women aged 50-69 years. Variables: Age at first CRC screening invitation, sex, number of screening invitations, number of screens, deprivation score, and uptake rate. Logistic regression models were used to assess the independent effect of sex, age at first invitation, deprivation, and the type of screening test offered on adherence. The uptake rate for guaiac fecal occult blood test (gFOBT) was 23.9%, and for the fecal immunochemical test (FIT), it was 37.4%. The overall rate of consistently screened invitees after seven rounds of screening was 14.2%, being 20.6% for those individuals who used FIT and 14.3% for those who used gFOBT. Factors associated with continued participation (consistent vs. inconsistent screenees) showed that the longitudinal adherence was associated with age, screening test used, and number of invitations. Continued participation was lower in individuals who were screened using FIT than among those screened using gFOBT [OR, 0.68; 95% confidence interval (CI), 0.57-0.81]. The overall rate of consistently screened invitees for colorectal cancer screening was higher with FIT than gFOBT. Studying the rate of individuals being current for screening may help to anticipate potential benefits before the long-term outcome data are available.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 50 条
  • [1] Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: A randomized, controlled trial
    Hoffman, Richard M.
    Steel, Susan
    Yee, Ellen F. T.
    Massie, Larry
    Schrader, Ronald M.
    Murata, Glen H.
    PREVENTIVE MEDICINE, 2010, 50 (5-6) : 297 - 299
  • [2] Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy
    Hol, L.
    van Leerdam, M. E.
    van Ballegooijen, M.
    van Vuuren, A. J.
    van Dekken, H.
    Reijerink, J. C. I. Y.
    van der Togt, A. C. M.
    Habbema, J. D. F.
    Kuipers, E. J.
    GUT, 2010, 59 (01) : 62 - 68
  • [3] Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy
    Sharp, L.
    Tilson, L.
    Whyte, S.
    O'Ceilleachair, A.
    Walsh, C.
    Usher, C.
    Tappenden, P.
    Chilcott, J.
    Staines, A.
    Barry, M.
    Comber, H.
    BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 805 - 816
  • [4] Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening
    Rabeneck, Linda
    Rumble, R. Bryan
    Thompson, Frank
    Mills, Michael
    Oleschuk, Curtis
    Whibley, Alexandra
    Messersmith, Hans
    Lewis, Nancy
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 26 (03) : 131 - 147
  • [5] Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme
    Guo, Feng
    De Brabander, Isabel
    Francart, Julie
    Candeur, Michel
    Polus, Marc
    Van Eycken, Liesbet
    Brenner, Hermann
    BRITISH JOURNAL OF CANCER, 2020, 122 (07) : 1109 - 1117
  • [6] Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy?
    Young, Graeme P.
    Fraser, Callum G.
    Halloran, Stephen P.
    Cole, Steven
    GUT, 2012, 61 (07) : 959 - 960
  • [7] Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis
    van Rossum, Leo G. M.
    van Rijn, Anne F.
    Verbeek, Andre L. M.
    van Oijen, Martijn G. H.
    Laheij, Robert J. F.
    Fockens, Paul
    Jansen, Jan B. M. J.
    Adang, Eddy M. M.
    Dekker, Evelien
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (08) : 1908 - 1917
  • [8] Fecal immunological blood test is more appealing than the guaiac-based test for colorectal cancer screening
    Le Pimpec, Fanny
    Moutel, Gregoire
    Piette, Christine
    Lievre, Astrid
    Bretagne, Jean-Francois
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (11) : 1267 - 1272
  • [9] Colorectal cancer in a population with a guaiac-based screening programme
    Navarro, Matilde
    Peris, Merce
    Binefa, Gemma
    Vanaclocha, Mercedes
    Losa, Ferran
    Fernandez, Esteve
    MEDICINA CLINICA, 2009, 132 (13): : 495 - 500
  • [10] Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer
    Faivre, J.
    Dancourt, V.
    Denis, B.
    Dorval, E.
    Piette, C.
    Perrin, Ph
    Bidan, J. M.
    Jard, C.
    Jung, S.
    Levillain, R.
    Viguier, J.
    Bretagne, J. F.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (16) : 2969 - 2976